Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer
Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California...
More... |
Re: Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Can
Inspiring, excinting, amazing.
Research is building a truly arsenal against breast cancer. |
All times are GMT -7. The time now is 05:04 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021